




ELSEVIER

Contents lists available at ScienceDirect

Molecular and Cellular Probes

journal homepage: www.elsevier.com/locate/ymcpr

Review

Q3 Application of immuno-PCR for the detection of early stage cancer

Q2 Amjad Hayat Khan, Esmaeil Sadroddiny*

Department of Medical Biotechnology, School of Advanced Technologies in Medicine, International Campus, Tehran University of Medical Sciences, Tehran, Iran

ARTICLE INFO

Article history:

Received 5 December 2015

Received in revised form

29 January 2016

Accepted 29 January 2016

Available online xxx

Keywords:

Early cancer detection

Biomarker

Cancer screening

Immuno-PCR

Immuno-polymerase chain reaction

A B S T R A C T

Cancer detection in premalignant stage is directly related with increase survival rate. Several biomarkers have been investigated and characterized for monitoring changes inside the cancerous cells. Although enzyme-linked immunosorbent assay (ELISA) is the method of choice in clinical practice for detecting biomarkers in serum/urine samples. However, in certain malignancies the amount of biomarkers before reaching metastasis, are too low to be detected by conventional ELISA. The seminal work of Sano et al. led to the development of highly sensitive and powerful detection method, the immuno-PCR (iPCR), which can detect very small amount of antigens/biomarkers. In spite of, several publications on iPCR sensitivity, it has not been recommended for clinical use and is limited to the scientific community only. In order to evaluate the importance of iPCR, we have made an effort to collect published studies, supporting the use of iPCR in detecting premalignant cancer.

© 2016 Published by Elsevier Ltd.

Contents

1. Introduction	00
2. Types of malignancies	00
2.1. Gastric cancer	00
2.2. Prostate cancer	00
2.3. Breast cancer	00
2.4. Nasopharyngeal carcinoma	00
2.5. Ovarian cancer	00
2.6. Bone cancer	00
2.7. Colorectal carcinoma	00
2.8. Hepatocellular carcinoma	00
3. Discussion	00
4. Conclusion	00
Conflict of interest	00
References	00

1. Introduction

According to the National Cancer Institute, North American

Association of Central Cancer Registries, and National Centre for Health Statistics, cancer is the leading cause of death throughout the world [1]. Cell division, growth, and differentiation get out of control in malignancy, resulting in the development of mass of cells called tumor, except in some types of leukemia. Sometime cancerous cells disseminate from the neoplasm and spread in blood stream, thereby, leading to the formation of secondary tumors, known as metastasis. Numerous FDA approved therapeutic antibodies are available on the market for addressing diverse

* Corresponding author. Department of Medical Biotechnology, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, No 88 Italia st., PO Box. 1417755469, Tehran, Iran.

E-mail address: sadroddiny@sina.tums.ac.ir (E. Sadroddiny).